--------------------------------------------------------------------------------

The following discussion and analysis provides information that management believes is relevant to an assessment and understanding of our condensed consolidated financial condition and results of operations. This discussion should be read in conjunction with the Consolidated Financial Statements included herewith, the footnotes thereto and the risk factors herein.

OVERVIEW

Comstock Inc. (together with its wholly-owned subsidiaries), is a leading
innovator of technologies that enable systemic decarbonization and circularity
by efficiently converting under-utilized waste and renewable natural resources
into fuels and electrification products that contribute to balancing global uses
and emissions of carbon. We expect to generate revenue by developing, using,
selling, and supporting new clean technologies that facilitate the more
efficient use of scarce natural resources. We are commercializing
environment-enhancing, material science-based technologies, products, and
processes including carbon neutral cellulosic bio-fuels and carbon reducing
lithium-ion battery ("LIB") metal recycling.

We intend to use our technologies to achieve exponential growth and extraordinary financial, natural and social returns by:

- building, owning, and operating a fleet of advanced carbon neutral extraction and

refining facilities;

- selling an array of complimentary process solutions and related services, and

- licensing selected technologies to qualified strategic partners.





Our objective is to generate over $16 billion in revenue on an annualized basis
by 2030, by responsibly producing and selling renewable energy products that
enable us, our clients, and their downstream stakeholders to reduce greenhouse
gas emissions by at least 100 million metric tons per year. Meeting that
objective would offset the equivalent of more than 234 million barrels per year
of fossil fuel, or about 6% of the U.S. transportation burn.

Our technologies unlock vast quantities of historically wasted and unused
feedstock supplies with enough short cycle carbon to offset many billions of
metric tons of long cycle fossil fuel emissions worldwide. Most of that
potential is provided by our Cellulosic Fuels technologies, which efficiently
convert wasted, unused, widely-available and rapidly-replenishable woody biomass
into intermediates and precursors for the production of carbon neutral oil,
ethanol, gasoline, renewable diesel, jet fuel, marine fuel, and other renewable
replacements for long cycle fossil derivatives. Our full portfolio of patented,
patent-pending and proprietary technologies includes many additional processes
that complement and add to that potential.

We expect to use our technologies to meet our 2030 objectives with less than
just 8% of the biomass residues produced annually in the U.S., however, we have
structured our business to achieve and enable exponentially greater gains. We
believe that the Earth's natural carbon cycle provides the simplest, fastest,
most scalable and most practical path for enabling systemic decarbonization and
achieving a net zero carbon world. Our strategic plan is consequently based on
innovating and using our technologies and renewable energy products to
simultaneously:

- reduce reliance on long cycle fossil fuels;

- shift supply chains that terminate in combustion to short cycle renewable fuels;

and

- lead and support the adoption and growth of a highly profitable, balanced worldwide

short cycle ecosystem that continuously offsets, recycles, and contributes to

neutralizing global carbon emissions by rapidly growing and replenishing vast

quantities of feedstock for renewable circular fuels

In that fashion, we plan to empower our clients, the industries in which they operate, and the populations they serve to Burn Less fossil fuels, to Burn Smarter with renewable fuels, to Burn Cleaner by recycling emissions into additional renewable fuels, and to thereby make disruptive contributions to global decarbonization and helping to achieve a net zero carbon world.

RECENT DEVELOPMENTS



Comstock historically focused on natural resource exploration, development, and
production, with an emphasis on mining gold and silver resources from its
extensive contiguous property holdings in the historic Comstock and Silver City
mining districts in Nevada (collectively, the "Comstock Mineral Estate"). We
subsequently focused on mineral exploration and development activities while
evaluating opportunities for the monetization of selected assets, debt
elimination and new investments.


--------------------------------------------------------------------------------

During 2022 and 2021, we completed a series of transactions that were designed
to build on our competencies and reposition us to capitalize on the global
transition to clean energy. Those transactions primarily included (i) our option
to sell Comstock Mining LLC, the owner of our Lucerne resource area in Storey
County, Nevada, and related permits, (ii) our acquisitions of 100% of Comstock
Innovations Corporation (F/K/A Plain Sight Innovations Corporation), 100% of
Comstock Engineering Corporation (F/K/A Renewable Process Solutions, Inc.), 100%
of MANA Corporation, and approximately 90% of LINICO Corporation, (iii) our
acquisition of the intellectual property portfolio from FLUX Photon Corporation,
and (iv) our investments of 48.19% of Quantum Generative Materials LLC, and
other minority investments. These transactions added the management, employees,
facilities, intellectual properties, and other assets needed to transform our
company and business into an emerging leader in the innovation and sustainable
production of renewable energy products, primarily by commercializing two new
lines of business, cellulosic fuels and electrification metals. Additional
information on these transactions is provided in Note 2 to our Condensed
Consolidated Financial Statements, Acquisitions and Investments.


The acquisitions and business integrations during 2021 and 2022 established our
new renewable energy platform for growth. We will innovate and commercialize
technologies that contribute to global decarbonization by efficiently converting
under-utilized natural resources into renewable fuels and electrification
products that shift supply chains away from fossil fuels. We will also lead and
support the adoption and growth of a balanced net zero ecosystem based on the
feedstocks unlocked by our technologies, with powerful embedded economic
incentives for our clients, their industries, and the populations they serve to
decarbonize.

We will rapidly achieve exponential growth and extraordinary financial, natural,
and social gains by building, owning, and operating a fleet of advanced carbon
neutral extraction and refining facilities, by selling an array of complimentary
process solutions and related services, and by licensing selected technologies
to qualified strategic partners

Our goal is to accelerate the commercialization of decarbonizing technologies
and generate billions in revenue on an annualized basis by 2030, by producing
and selling renewable energy products that enable us, our clients, and their
downstream stakeholders to reduce greenhouse gas emissions by at least 100
million metric tons per year. Meeting that objective would offset more than 234
million barrels per year of fossil fuel, or about 6% of the U.S. transportation
burn, and require an estimated 8% of the existing biomass residues produced
annually in the U.S.

We also announced a significant expansion of our leading cellulosic technology
portfolio by filing for a new patent covering breakthrough pathways to produce
renewable diesel, marine, sustainable aviation fuel ("SAF") and gasoline from
woody biomass, at dramatically improved yield, efficiency, and cost in
comparison to all known methods. These technology advancements enable a new
sustainable feedstock capable of neutralizing a substantial share of current
U.S. mobility emissions.

Renewable fuels provide a critical opportunity for decarbonization, however,
most of the existing U.S. renewable fuel refineries draw from the same limited
pool of constrained feedstocks. Comstock's plans to decarbonize with renewable
fuels involves abundant feedstocks that are not used today, enabling a vast
untapped energy source with superior benefits.

Based on current performance data, Comstock projects best-in-class renewable
fuel yields exceeding 80 gallons per dry ton (on a gasoline gallon equivalent
basis), with lifecycle greenhouse gas emissions reductions well exceeding 80%
over petroleum.

About half of America's historical forest lands were clear cut for less
productive uses. Restoring and using just about a quarter of that amount, or
approximately 140 million acres, to sustainably grow, harvest, and replant
fast-growing trees for use in producing renewable fuels would be sufficient to
permanently neutralize more than 40% of America's mobility emissions.

Such scales are achievable by leveraging existing external fuel infrastructure.
Our expanded team has extensive experience in the renewable fuels industry,
having designed and built several dozen renewable fuel production facilities in
the U.S. We have already made remarkable progress. We are currently building
commercial pilot scale cellulosic fuels and LIB facilities, and we are preparing
to commence operations at our full-scale lithium-ion battery recycling facility
later this year. We have also made significant strides in developing and
establishing our new facilities and forging new revenue and licensing streams
that we will soon share.

We have also made meaningful progress and will complete the monetization of our
non-strategic assets, as quickly as possible, while funding our new businesses
and limiting our outlook and focus to the objectives outlined above.

COVID-19

--------------------------------------------------------------------------------



The outbreak in 2020 of the novel coronavirus ("COVID-19") resulted in
governments worldwide enacting emergency measures to combat the spread of the
virus. These measures, including the implementation of social distancing
measures, quarantine periods and travel bans, have caused material disruptions
to many businesses and negatively impacted economic activities. Global equity
markets have experienced significant volatility. Governments and their central
banks have reacted with significant fiscal and monetary interventions designed
to mitigate the impacts and stabilize economic conditions. The impact and
ultimate duration of the COVID-19 outbreak is currently unknown, as is the
efficacy of these governmental interventions.

For more than two years in Nevada, local governments, state health officials,
emergency managers, local health authorities and community partners have come
together in a statewide response to COVID-19. Processes continue to be in place
to support testing, contact tracing, disease investigation and vaccine rollout
in communities throughout the state. We are operating in alignment with these
guidelines for protecting the health of our employees, partners and suppliers.

On May 20, 2022, Nevada Governor Steve Sisolak effected the end of the
Declaration of Emergency, originally declared on March 12, 2020, to facilitate
the State's response to the COVID-19 pandemic. The Declaration and subsequent
directives ensured the State of Nevada could effectively prevent infections,
reduce the impacts on patient care in the healthcare system and reduce the
number of Nevadans who died from the disease caused by the virus.

COMPARATIVE FINANCIAL INFORMATION

Below we set forth a summary of comparative financial information for the three months ended June 30, 2022 and 2021:



                                                               6/30/22                6/30/21               Change
Revenue                                                    $      52,925          $     54,625          $     (1,700)

Cost of goods sold                                                     -                     -                     -
Gross profit                                                      52,925                54,625                (1,700)

Selling, general and administrative expenses                   2,508,573             1,649,711               858,862
Research and development                                       2,579,150                     -             2,579,150
Depreciation and amortization                                    808,894               114,631               694,263
Total operating expenses                                       5,896,617             1,764,342             4,132,275

Loss from operations                                          (5,843,692)           (1,709,717)           (4,133,975)

Other Income (Expense)
Gain (loss) on investments                                      (298,801)           (1,120,571)              821,770
Interest expense                                                (312,026)                  253              (312,279)
Interest income                                                    1,491               231,496              (230,005)
Change in fair value of derivative instruments                (8,190,000)           (2,489,999)           (5,700,001)

Recovery (impairment) of investments and intangible assets 895,204

                  -               895,204
Other income (expense)                                          (342,773)           (1,232,454)              889,681
Total other income (expense), net                             (8,246,905)           (4,611,275)           (3,635,630)

Net income (loss)                                          $ (14,090,597)         $ (6,320,992)           (7,769,605)

Net loss attributable to noncontrolling interest           $    (323,751)         $          -              (323,751)

Net income (loss) attributable to Comstock Inc,            $ (13,766,846)         $ (6,320,992)         $ (7,445,854)



RESULTS OF OPERATIONS

--------------------------------------------------------------------------------

Three Months Ended June 30, 2022 Compared to Three Months Ended June 30, 2021



Revenues and gross profit for the three months ended June 30, 2022, decreased
slightly to $52,925 from $54,625 for the same period in 2021, as a result of the
loss of one lessee.

Selling, general and administrative expense for the three months ended June 30,
2022 increased to $2,508,573 from $1,649,711 for 2021, primarily as a result of
$0.5 million increase in personnel, insurance and other costs related to 2021
acquisitions and $0.4 million increase in legal and professional fees related to
our acquisitions, corporate governance and other transactions.

Research and development expenses for the three months ended June 30, 2022 were
$2,579,150 and included costs related to development of a pilot scale system for
processing woody biomass into intermediate materials that can be converted into
paper products and fuels and the pilot scale system for crushing and separating
lithium ion batteries. These systems will be used to validate the processes and
develop parameters for upscaling these renewable technologies. Our Comstock
Engineering, Comstock Innovations and LINICO subsidiaries, which were acquired
in the second, third and fourth quarters of 2021, respectively, are leading the
developments of these commercializing technologies. No similar costs were
incurred in the second quarter 2021.

Depreciation and amortization increased by $694,263 during the three months
ended June 30, 2022, compared to the same 2021 period, related to intangible and
right of use asset amortization related to 2021 acquisitions, primarily during
the last half of 2021.

During the three months ended June 30, 2022, the Company recorded a loss on
investments of $298,801, as compared to a loss on investments for the same 2021
period of $1,120,571. The 2022 loss was primarily due to realized losses on
sales of 6,813,314 shares of Tonogold common stock. The 2021 loss was primarily
due to a decrease in fair value of Tonogold common stock of $938,573 and
realized losses on sales of Tonogold shares of $180,254, and a decrease in the
market value of other securities.

The change in fair value of our derivative instruments increased by $5,700,001
for the three months ended June 30, 2022 as compared to the change in fair value
of our derivatives for the same period in 2021, as a result of a decrease in the
Company's share price in connection with potential make whole obligations for
minimum value commitments on the Company's common shares, including $3,150,000
for Quantum Generative Materials LLC ("GenMat"), $1,365,000 from the Haywood
acquisition and $3,675,000 from the additional LINICO investment made on
December 30, 2021. The change in fair value from the three months ended June 30,
2021, was attributable to a $360,000 gain for GenMat offset by a $2,849,999 loss
on the LINICO derivative asset.

We recognized a recovery of credit losses on the MCU-P note receivable for the
three months ended June 30, 2022 of $895,204 which was primarily a result of
cash distributions to the Company from MCU and MCU-P.
Other expenses, net for the three months ended June 30, 2022 were $342,773,
which primarily consisted of losses from our equity method investments of
$311,917 and other losses of $30,856.

Other expenses, net for the three months ended June 30, 2021 were $1,232,454,
primarily from losses from the change in fair value of the Tonogold note
receivable of $1,173,000 and Tono Note amendment fee income of $100,000, and
losses from our equity method investments of $159,313, and $141 other expense.

Interest income decreased by $230,005 for the three months ended June 30, 2022,
as compared to 2021, as a result of the transaction that extinguished the
Tonogold note in exchange for the 100% membership interest in Comstock LLC and
the extinguishment of the MCU-P note that was exchanged for the MCU assets, both
of which are no longer accruing interest.

Interest expense increased by $312,279 for the three months ended June 30, 2022,
as compared to 2021, primarily due to $0.2 million in interest on the AQMS lease
liability acquired with the LINICO acquisition at the end of Q4 2021 and
$0.1 million in interest and amortization of OID on GHF note, which originated
in Dec 2021.

Net loss was $14,090,597 for the three months ended June 30, 2022, as compared
to net loss of $6,320,992 for the same period in 2021. The $7,769,605 increase
in net loss primarily resulted from a $5,700,001 increase in losses from the
estimated fair value of the derivative assets related to LINICO, GenMat and
Haywood, an increase of $2,579,150 for research and development expenses, an
increase of $858,862 in selling, general and administrative expenses, partially
offset by a $895,204 recovery of losses related to the MCU-P note receivable.

--------------------------------------------------------------------------------

Below we set forth a summary of comparative financial information for the six months ended June 30, 2022 and 2021:



                                                              6/30/2022             6/30/2021               Change
Revenue                                                    $     107,550          $   103,125          $       4,425

Cost of goods sold                                                     -                    -                      -
Gross profit                                                     107,550              103,125                  4,425

Selling, general and administrative expenses                   4,911,339            1,184,485              3,726,854
Research and development                                       3,774,568                    -              3,774,568
Depreciation and amortization                                  1,653,423              230,599              1,422,824
Total operating expenses                                      10,339,330            1,415,084              8,924,246

Loss from operations                                         (10,231,780)          (1,311,959)            (8,919,821)

Other Income (Expense)
Gain (loss) on investments                                        52,823           (1,827,482)             1,880,305
Interest expense                                                (636,750)            (144,576)              (492,174)
Interest income                                                  358,352              386,969                (28,617)
Change in fair value of derivative instruments                (5,125,000)           4,997,250            (10,122,250)

Recovery (impairment) of investments and intangible assets (3,581,685)

                 -             (3,581,685)
Other income (expense)                                        (1,473,580)            (232,963)            (1,240,617)
Total other income (expense), net                            (10,405,840)           3,179,198            (13,585,038)

Net income (loss)                                          $ (20,637,620)         $ 1,867,239            (22,504,859)

Net loss attributable to noncontrolling interest           $    (492,219)         $         -               (492,219)

Net income (loss) attributable to Comstock Inc,            $ (20,145,401)         $ 1,867,239          $ (22,012,640)



RESULTS OF OPERATIONS

Six Months Ended June 30, 2022 Compared to Six Months Ended June 30, 2021

Revenues and gross profit for the six months ended June 30, 2022, increased to $107,550 from $103,125 for the same period in 2021, as a result of a slight increase in rental revenue from its higher rental income from its Gold Hill Hotel lease, which commenced in February 2021.



Revenue, costs of sales and gross profit in future periods will vary
significantly depending on a number of factors, including the amount of
renewable energy products that we produce and sell, the market prices for those
products, the extent to which we secure and collect reasonable royalties, the
degree to which we can provide event-driven engineering services, and the costs
associated with each component of the aforementioned revenues.

Selling, general and administrative expense for the six months ended June 30,
2022 increased to $4,911,339 from $1,184,485 for 2021, primarily as a result of
2021 adjustments to the reclamation liability estimate, which was reduced by
$0.9 million as a result of extending the estimated reclamation timing to five
years, and the Northern Comstock accelerated payment reimbursed by Tonogold of
$0.8 million, which adjustments reduced expenses during the six months ended
June 30, 2021. In addition, we had an increase of approximately $0.9 million
from higher employee costs related to new employees from 2021 acquisitions

--------------------------------------------------------------------------------

during the six months ended June 30, 2022, $0.7 million increase in legal and accounting fees and other costs related to the our acquisitions, corporate governance and transactions.



Research and development expenses for the six months ended June 30, 2022 were
$3,774,568 and included costs related to development of a pilot scale system for
processing woody biomass into intermediate materials that can be converted into
paper products and fuels and the pilot scale system for crushing and separating
lithium ion batteries. These systems will be used to validate the processes and
develop parameters for upscaling these renewable technologies. Our Comstock
Engineering, Comstock Innovations and LINICO subsidiaries, which were acquired
in the second, third and fourth quarters of 2021, respectively, are leading the
developments of these commercializing technologies. No similar costs were
incurred in the first half of 2021.

Depreciation and amortization increased by $1,422,824 during the six months ended June 30, 2022, compared to the same period in 2021, related to intangible and right of use asset amortization related to 2021 acquisitions, which primarily occurred in the last half of 2021.



During the six months ended June 30, 2022, the Company recorded a gain on
investments of $52,823, as compared to a loss on investments for the same period
in 2021 of $1,827,482. The 2022 gain was primarily a result of sales of
8,065,924 shares of Tonogold stock at an average price of $0.12 per share
compared to the share price of $0.11 as of December 31, 2021. The 2021 loss was
primarily due to a decrease in fair value of $1,829,611, and a loss of $13,409
from a decrease in the market value of other securities.

The change in fair value of our derivative instruments was a loss of $5,125,000
for the six months ended June 30, 2022 as compared to a gain of $4,997,250 for
the same period in 2021 as a result of a decrease in the Company's share price
in connection with potential make whole obligations for minimum value
commitments on the Company's common shares. The change in fair value of
derivatives for the six months ended June 30, 2022 included losses of $2,010,000
for GenMat, $1,365,000 for the Haywood acquisition, $2,345,000 from the
additional LINICO investment made on December 30, 2021, partially offset by a
gain of $595,000 for LP Biosciences LLC ("LPB"). The increase from the six
months ended June 30, 2021, was attributable to an increase in the fair values
of the GenMat derivative asset of $360,000, the MCU derivative asset of $497,250
and the LINICO derivative asset of $4,140,000.

Impairment losses net of recoveries for the six months ended June 30, 2022 were
$3,581,685 on investments in MCU and MCU-P and the MCU-P note receivable, which
were deemed unrecoverable as of March 31, 2022. In June 2022, we recovered
$895,204 in cash related to the investments. We also recognized impairment
losses of $338,035 related to the FPC intangible asset, and $595,000 related to
the LPB investment prior to settlement that resulted in the return to the
Company of 3,500,000 of its common shares.
Other expenses, net for the six months ended June 30, 2022 were $1,473,580,
which primarily consisted of a reduction in value of the Tonogold note
receivable of $605,000, losses from our equity method investments of $578,819,
LPB settlement expense of $250,000 and other losses of $39,761.

Other expenses, net for the six months ended June 30, 2021 were $232,963, which
primarily consisted of losses from the change in fair value of the Tonogold note
receivable of $427,500 and losses from our equity method investments of
$190,767, partially offset by Tonogold note amendment fee income of $362,500 and
other income of $22,804.

Interest income decreased by $28,617 for the six months ended June 30, 2022, as
compared to 2021, as a result of the transaction in which the Tonogold note was
exchanged for Comstock LLC stock and the write-off of the MCU-P note receivable,
which was forgiven in exchange for the MCU assets, both of which are no longer
accruing interest.

Interest expense increased by $492,174 for the six months ended June 30, 2022,
as compared to 2021, primarily due to $0.4 million in interest on the AQMS lease
liability acquired with the LINICO acquisition at the end of 2021 and
$0.2 million in interest and amortization of OID on the GHF note, which
originated in late December 2021, partially offset by $0.14 million in interest
on prior promissory notes that were paid off in Q1 2022.

Net loss was $20,637,620 for the six months ended June 30, 2022, as compared to
a net income of $1,867,239 for the same period in 2021. The $22,504,859 decrease
in net income primarily resulted from a $10,122,250 decrease in the estimated
fair value of the derivative assets and liabilities, a $3,581,685 increase in
impairment losses on MCU and MCU-P related investments and notes receivable, net
and to a lesser extent, the Flux Photon intangible. $3,726,854, increase in
selling, general and administrative expenses, $3,774,568 increase in research
and development expenses. A $1,240,617 increase in other expenses somewhat
offset the $895,204 recovery of losses on the MCU-P note receivable.

--------------------------------------------------------------------------------





OUTLOOK

The 2021 cellulosic fuels and lithium-ion battery recycling acquisitions and
business integrations established our new renewable energy platform for growth.
We will innovate and commercialize technologies that contribute to global
decarbonization by efficiently converting under-utilized natural resources into
renewable fuels and electrification products that shift supply chains away from
fossil fuels. We will also lead the adoption and growth of a balanced net zero
ecosystem based on an abundance of woody biomass feedstocks unlocked by our
cellulosic fuels technologies, with powerful economic benefits to us, our
clients, their industries, and the populations they serve to decarbonize.

These two renewable energy businesses position us to achieve exponential growth
and extraordinary financial, natural, and social gains by building, owning, and
operating a fleet of advanced carbon neutral extraction and refining facilities
and lithium-ion battery recycling facilities, producing an array of renewable
fuels and electrification products.

Our objective is to accelerate the commercialization of these decarbonizing
technologies, and generate billions in revenue on an annualized basis by 2030,
by producing and selling renewable energy products that enable us and our
customers to reduce greenhouse gas emissions by at least 100 million metric tons
per year. Meeting that objective would offset more than 234 million barrels per
year of fossil fuel, or about 6% of the U.S. transportation burn, and only
require an estimated 8% of the existing biomass residues produced annually in
the U.S.

Such scales are achievable quickly by leveraging existing external fuel
infrastructure. Our expanded team has extensive experience in the renewable
fuels industry, having designed and built several dozen renewable fuel
production facilities in the U.S. We have already made remarkable progress. We
are currently building commercial pilot scale cellulosic fuels and LIB
facilities, and we are preparing pilot-scale operations of our crushing and
separating systems that will produce mineral-rich black mass at our 137,000
square foot state of the art manufacturing facility later this year and also
deploy our lithium extraction pilot capability in the same facility, both in
2023.

Our pilot scale cellulosic fuel system will also be operational in 2023, positioning the scaling and ramp of our first cellulosic fuel bio refinery that will produce an array of bio intermediaries and biofuels for today's infrastructure.



We expect to receive our operating permit for battery metal processing during
the fourth quarter of 2022, and our air quality permit in the first quarter of
2023. We are currently engaged with and building a coalition of strategic
suppliers, partners, and/or customers in both of our renewable businesses.

We have also made meaningful progress and will complete the monetization of our
non-strategic assets, during 2022, while funding our new businesses and limiting
our outlook and focus to the objectives outlined above.

LIQUIDITY AND CAPITAL RESOURCES



Our financial position and liquidity is based on our ability to generate cash
flows from our operations, as well as our net sources of capital from financing
as generally compared to our net uses of capital from investing activities. Our
cash balances at June 30, 2022 and December 31, 2021 were $4,345,315 and
$5,912,188, respectively. The Company had current assets of $11,088,560 and
current liabilities of $30,935,063, representing working capital deficit, net of
cash, of $24,191,818 at June 30, 2022.

During the six months ended June 30, 2022, we used $7,714,703 in cash in our
operating activities, provided $516,145 in our investing activities, and sourced
$5,631,685 from our financing activities. During the six months ended June 30,
2021, we used $3,326,611 in cash in our operating activities, and $7,075,315 in
our investing activities and we sourced $13,222,530 from our financing
activities. During the six months ended June 30, 2022, 7,545,620 common shares
were issued through equity issuance and private placement agreements at an
average price per share of $0.72 and net proceeds of $3,457,084, net of cash
issuance fees of $213,000.

On April 12, 2022, the Company entered into an equity purchase agreement (the
"Purchase Agreement") with Leviston Resources LLC ("Leviston") for the purchase
of up to $10,000,000 worth of shares of the Company's common stock from time to
time, at the Company's option, on terms deemed favorable to the Company. Any
shares offered and sold will be issued pursuant to the Company's shelf
registration statement on Form S-3 and the related prospectus (File No.
333-263930) filed by the Company with the U.S. Securities and Exchange
Commission pursuant to the Securities Act of 1933 (the "Securities Act").

--------------------------------------------------------------------------------

Sales of common stock, if any, under the Purchase Agreement may be made in sales
deemed to be "at-the-market" equity offerings as defined in Rule 415 promulgated
under the Securities Act, at a discount of 10% to the volume weighted average
sales price of the common stock on the date that Leviston receives a capital
call from the Company. In consideration of Leviston's agreement to enter the
Purchase Agreement, the Company agreed to deliver additional shares of common
stock to Leviston, for no additional consideration, on the first settlement date
with respect to a put notice delivered by the Company. For the three and six
months ended June 30, 2022, we issued to Leviston 4,377,697 common shares with
an aggregate sales price of $3,460,000, at an average price per share of $0.79,
and an additional 343,883 common shares at a fair value of $500,000 in
commitment and due diligence fees. As of June 30, 2022, the 2022 Leviston Sales
Agreement has $6,540,000 of remaining capacity.

On June 21, 2022, the Company entered into an equity purchase agreement (the
"Purchase Agreement") with Tysadco Partners, LLC ("Tysadco") for the private
placement of 3,076,923 common shares at a purchase price of $0.65 per share. The
Company paid $140,000 in cash and delivered 57,143 common shares with a fair
value of $40,000 to the placement agent in connection with such sale.

The Company also entered into an agreement for the purchase of up to $10,000,000
worth of shares of the Company's common stock from time to time, at the
Company's option. Any shares offered and sold to Tysadco will be registered for
resale pursuant to a registration statement on Form S-1 filed with U.S.
Securities and Exchange Commission pursuant to the Securities Act of 1933 (the
"Securities Act"). Such sale was exempt from registration pursuant to Section
4(a)(2) of the Securities Act. The Company will pay commissions equal to 5% of
the offering proceeds to the placement agent in connection with any such sale.
In consideration to enter the Purchase Agreement, the Company delivered 428,571
additional shares of common stock to Tysadco.

Sales of common stock, if any, under the Purchase Agreement are made at a 10%
discount to the volume weighted average sales price of the common stock on the
date that Tysadco receives a capital call from the Company.

We intend to fund our operations over the next twelve months from existing cash
and cash equivalents, planned sales and profits from our cellulosic technology
and related engineering services, planned sales of strategic and other
investments, including our existing non-mining assets and investments in
Tonogold and previously funded capital into our LINICO subsidiary. Based on
these expected funding sources, management believes we will have sufficient
funds to sustain our operations and meet our commitments under our investment
agreements during the 12 months following the date of issuance of the condensed
consolidated financial statements included herein. While we have been successful
in the past in obtaining the necessary capital to support our operations,
including registered equity financings from our existing shelf registration
statement, borrowings and various other means, there is no assurance we will be
able to obtain additional equity capital or other financing, if needed.

Net cash used in operating activities for the six months ended June 30, 2022
increased by $4,388,092 from the same period in 2021 primarily from net
increases in operating costs, partially offset by an increase in net sources of
cash for working capital.

Net cash used in investing activities for the six months ended June 30, 2022
decreased by $7,591,460 from the comparable six months ended 2021 primarily due
to decreases of $2,735,000 in advances to SSOF, cash payments to LINICO of
$2,000,000 and GenMat of $2,000,000, and loans to Comstock IP Holdings and LP
Biosciences of $1,161,258, and an $820,000 use for the MCU-P note receivable in
2021, partially offset by 2022 source of cash proceeds from the $750,000
Tonogold option payment received.

Net cash provided in financing activities for the six months ended June 30, 2022
decreased $7,590,845 compared to the same period in 2021, primarily as a result
of reduced net proceeds from the issuance of common stock of $11,780,000,
partially offset by reduced principal payments on debt of $3,448,288 and
contributions of $500,000 from AQMS for additional shares in LINICO.

Risks to our liquidity could result from future operating expenditures above
management's expectations, including but not limited to exploration,
pre-development, research and development, selling, general and administrative,
and investment related expenditures in excess of repayments of the advances to
SSOF and sale of the Silver Springs Properties, amounts to be raised from the
issuance of equity under our existing shelf registration statement, declines in
the market value of properties planned for sale, or declines in the share price
of our common stock that would adversely affect our results of operations,
financial condition and cash flows. If we were unable to obtain any necessary
additional funds, this could have an immediate material adverse effect on
liquidity and raise substantial doubt about our ability to continue as a going
concern. In such case, we could be required to limit or discontinue certain
business plans, activities or operations, reduce or delay certain capital
expenditures or

--------------------------------------------------------------------------------

investments, or sell certain assets or businesses. There can be no assurance
that we would be able to take any such actions on favorable terms, in a timely
manner, or at all.

CRITICAL ACCOUNTING ESTIMATES

There have been no significant changes to the critical accounting estimates disclosed in Management's Discussion and Analysis of Financial Condition and Results of Operations in our 2021 Form 10-K.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses